Drugs / ENV-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06422884 | Nov 2024 → Oct 2026 expected | idiopathic pulmonary fibrosis | Endeavor Biomedicines, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05199584 | May 2022 → Feb 2024 | — | Endeavor Biomedicines, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENV-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06422884 ↗ |
| Known as | taladegib | “ENV-101 (taladegib)” NCT05199584 ↗ |
| Action | Inhibit | “a potent Hedgehog (Hh) pathway inhibitor” NCT05199584 ↗ |
| Route | Oral | “oral tablet, dosed once a day” NCT06422884 ↗ |